Dianthus Therapeutics, Inc. (DNTH)

NASDAQ: DNTH · IEX Real-Time Price · USD
25.26
-0.74 (-2.85%)
Jun 17, 2024, 4:00 PM EDT - Market closed
-2.85%
Market Cap 741.37M
Revenue (ttm) 2.26M
Net Income (ttm) -42.36M
Shares Out 29.35M
EPS (ttm) 3.83
PE Ratio 6.60
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 412,461
Open 25.63
Previous Close 26.00
Day's Range 24.53 - 25.97
52-Week Range 0.62 - 33.77
Beta n/a
Analysts Strong Buy
Price Target 42.40 (+67.85%)
Earnings Date Aug 3, 2024

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 53
Stock Exchange NASDAQ
Ticker Symbol DNTH
Full Company Profile

Financial Performance

In 2023, DNTH's revenue was $2.83 million, a decrease of -55.96% compared to the previous year's $6.42 million. Losses were -$43.56 million, 53.0% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price forecast is $42.4, which is an increase of 67.85% from the latest price.

Price Target
$42.4
(67.85% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial i...

6 days ago - GlobeNewsWire

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

18 days ago - GlobeNewsWire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H'25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor Neurop...

5 weeks ago - GlobeNewsWire

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

5 weeks ago - GlobeNewsWire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody co...

6 weeks ago - GlobeNewsWire

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibod...

2 months ago - GlobeNewsWire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1'24 with top-line results  anticipated in 2H'25

3 months ago - GlobeNewsWire

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next gene...

3 months ago - GlobeNewsWire

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

Top-line results from gMG MaGic trial anticipated in 2H 2025 Building a neuromuscular franchise with DNTH103 through additional planned Phase 2 trials in Multifocal Motor Neuropathy (MMN) and Chronic ...

4 months ago - GlobeNewsWire

Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

The combined company will operate as “Dianthus Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “DNTH” effective Tuesday, September 12, 2023 The combined company will op...

10 months ago - GlobeNewsWire

MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Magenta Therap...

11 months ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus

MILWAUKEE , May 3, 2023 /PRNewswire/ -- Ademi LLP is investigating Magenta (Nasdaq: MGTA) for possible breaches of fiduciary duty and other violations of law in its transaction with Dianthus.  Click h...

1 year ago - PRNewsWire

MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Magenta Therapeutics, Inc. (NASDAQ: MGTA) and Dianthus Therapeutics, Inc. is fair to Ma...

1 year ago - Business Wire

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus' portfolio of next-generation antibody complement therapeutics

1 year ago - GlobeNewsWire

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously ad...

1 year ago - GlobeNewsWire

Magenta Therapeutics to Explore Strategic Alternatives

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company focused on improving stem cell transplantation, today announced that it ...

1 year ago - GlobeNewsWire

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Pha...

1 year ago - GlobeNewsWire

Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial

– Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities –

1 year ago - GlobeNewsWire

Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; tran...

1 year ago - GlobeNewsWire

Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem ...

1 year ago - GlobeNewsWire

Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; ...

1 year ago - GlobeNewsWire

Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

– Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism –

1 year ago - GlobeNewsWire

Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem ...

1 year ago - GlobeNewsWire

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem ...

1 year ago - GlobeNewsWire

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions, rapid drug clearance and a favorable tolerability pro...

2 years ago - GlobeNewsWire